Can we count your visit with Google Analytics? No ads, no profiles. Details
EDSA
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural - clinical-stage microcap (~$18M cap, no revenue) with a single high-conviction asset: EB05, an anti-TLR4 monoclonal antibody. Phase 2 ARDS trial showed 68% reduction in 28-day mortality in mechanically-ventilated patients (n=58).
DoD partnership funds the Phase 3 ARDS readout - non-dilutive capital plus regulatory credibility.
Bull - (1) ARDS has no approved drug; EB05 holds FDA Fast Track + DoD funding for Phase 3; (2) TLR4 mechanism extends across indications (urticaria Phase 2 readout near-term); (3) <$20M cap on a Phase 3 asset = asymmetric optionality if data prints; (4) cash runway extended by DoD non-dilutive grants; (5) sub-3M float post-2024 reverse split limits supply.
Bear - (1) single-asset binary - EB05 failure ends the thesis; (2) microcap biotech dilution risk (frequent ATMs / registered directs); (3) ARDS Phase 2 mortality signal on small n=58 historically de-risks poorly in Phase 3; (4) Nasdaq listing compliance pressure (sub-$1 stretches historically); (5) zero analyst coverage, illiquid tape - execution on any exit is the trade.
It reads our $EDSA data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
No major news in the last 7 days for EDSA - only listicles and opinion pieces, which we filter out by default. See everything anyway.